A Double-blind Multicenter Two-arm Randomized Placebo-controlled Phase-III Clinical Study to Evaluate the Effectiveness and Safety of Thymosin α1 as an Add-on Treatment to Existing Standard of Care Treatment in Moderate-to-severe COVID-19 Patients.

Indian J Crit Care Med · 2022 · PMC9363815 · PMID 36042753

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

distinctly significantno p-value reported

This was also accompanied by a distinctly significant improvement in most of the biomarkers assessed such as TLC, CD4, CD8, CRP, LDH, and IL-6 levels in all patients after treatment with Tα1 for 7 consecutive days.

also in 48 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.